PrEP

Let’s START at the very beginning

An important development in the worldwide treatment and care of HIV-infected individuals was announced earlier this week. Read on to find out what this means for HIV treatment practices moving forward…

Source: http://www.capitalwired.com/wp-content/uploads/2015/05/113.jpg

(more…)

Advertisements

Are we PrEPared to eradicate HIV?

Source: NYDailyNews.com

In the past few months, support for HIV pre-exposure prophylaxis (PrEP; Truvada) has grown substantially. The CDC and WHO now endorse it, as does New York State Governor Cuomo who recently announced a multi-pronged plan to reduce the rate of new HIV infections in the state by 75% before 2020. However, the role of PrEP in curbing HIV transmission is still hotly debated – who should take it, who should pay for it, and whether or not it will work on a population level. Its price tag is about $10,000/year to insurers, it requires daily adherence for maximum benefit, and involves periodic testing to monitor a patient’s HIV status. Part of the concern is that PrEP’s effectiveness may be affected by two behavioral phenomena often experienced in health promotion: self-selection and risk compensation. (more…)